IGF-I assays: Current assay methodologies and their limitations

Pituitary

Volumn 10, Issue 2, 2007, Pages 121-128

  Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Acromegaly; Growth hormone deficiency; Insulin likegrowth factor binding proteins; Insulin likegrowth factors; Radioimmunoassay

Indexed keywords

ANTISERUM; GROWTH HORMONE; REAGENT; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ACROMEGALY; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; LABORATORY DIAGNOSIS; NORMAL VALUE; PRIORITY JOURNAL; QUALITY CONTROL; RADIOIMMUNOASSAY; REFERENCE VALUE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

ACROMEGALY; CLINICAL LABORATORY TECHNIQUES; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; OBSERVER VARIATION; RECEPTOR, IGF TYPE 1; REFERENCE STANDARDS; VALIDATION STUDIES AS TOPIC;

EID: 34249886308     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-007-0032-z     Document Type: Article

References (36)

1. Hoffman DM, O'Sullivan AJ, Baxter RC, Ho K (1994) Diagnosis of growth hormone deficiency in adults. Lancet 343:1064
2. O'Connor KG, Tobin JD, Harman SM, Plato CC, Roy TA, Sherman SS, et al (1998) Serum levels of insulin-like growth factor-I are related to age and not to body composition in healthy women and men. J Gerontol A Biol Sci Med Sci 53:176
3. Brabant G, van zur Muhlen A, Wuster C, Ranke MB, Kratzche J, Kiess W et al (2003) Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: Results from a multicenter study. Horm Res 60:53
4. Massart C, Poirier JY (2006) Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: Comparison of four immunoassays. Clin Chim Acta 373:176
5. Underwood LE, Thissen JP, Lemozy S, Ketleslegers JM, Clemmons DR (1994) Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res 42:145
6. Smith WJ, Nam TJ, Underwood LE, Busby WH, Celnicker A, Clemmons DR (1993) Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3 and IGF-I for assessing growth hormone status in short children. J Clin Endocrinol Metab 77:1294
7. Milani D. Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg D (2004) Variability and reliability of single serum IGF-I measurements: Impact on determining predictability of risk ratios in disease development. J Clin Endocrinol 89:2271
8. Furlantello RW, Underwood Le Van Wyk JJ, D'Ercole AJ (1977) Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest 60:648
9. Dean HJ, Kellett JG, Bala RM, Guyda HJ, Bhaumick B, Posner BI, et al (1982) The effect of growth hormone treatment on somatomedin levels in growth hormone-deficient children. J Clin Endocrinol Metab 55:1167
10. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE (1979) Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 301:1138
11. Daughaday WH, Ward AP, Goldberg AC, Trivedi B, Kapadia M (1982) Characterization of somatomedin binding in human serum by ultracentrifugation and gel filtration. J Clin Endocrinol Metab 55:916
12. Kaurmann U, Zapf J, Froesch ER (1979) The effect of different extraction procedures on two different molecular weight species of serum NSILA and on the carrier protein of small molecular weigh NSILA (NSILA-S). Acta Endocrinol 90:637
13. Daughaday WH, Parker KA, Borowsky S, Trivedi B, Kapadia M (1982) Measurement of somatomedin-related peptides in fetal, neonatal, and maternal rat serum by insulin-like growth factor (IGF) I radioimmunoassay, IGF-II radioreceptor assay (RRA) and multiplication-stimulating activity RRA after acid-ethanol extraction. Endocrinology 110:575
14. Mesiano S, Young IR, Braune CA, Thorbun GD (1988) Failure of acid-ethanol treatment to prevent interference by binding protein in radioligand assays for insulin-like growth factors. J Endocrinol 119:453
15. Mohan S, Baylink DJ (1995) Development of a simple valid method for the complete removal of insulin-like growth factor (IGF)-binding proteins from IGFs in the human serum and other biological fluids: Comparison with acid-ethanol treatment and C18 Sep-Pak separation. J Clin Endocrinol Metab 80:637
16. Blum WF, Breier BH (1994) Radioimmunoassays for IGFs and IGFBPs. Growth Regul 1:11
17. Schuller AG, Lindenbergh-Kortieve DJ, de Boer WI, Zwarthoff EC, Drop SL (1993) Localization of the epitope of a monoclonal antibody against human insulin-like growth factor binding protein-1, functionally interfering with insulin-like growth factor binding. Growth Regul 3:32
18. Khosravi MG, Diamandi A, Mistry J, Lee PD (1996) Noncompetitive ELISA for human serum insulin-like growth factor-I. Clin Chem 42:1147
19. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K et al (1994) Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: Relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78:744
20. Frystyk J (2004) Free insulin-like growth factors-measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 14:337
21. Chatelain PG, Van Wyk J, Copeland KC, Biethen SL, Underwood LE (1983) Effect of in vitro action of serum proteases or exposure to acid on measurable immunoreactive somatomedin-C in serum. J Clin Endocrinol Metab 56:376
22. Renehan A, Jones J, O'Dwyer ST, Shalet SM (2003) Determine of IGF-I, IGF-II, IGFBP-2 and IGFBP-3 levels in serum and plasma: Comparisons using the Bland-Altman method. Growth Horm IGF Res 13:341
23. Harris TG, Strickler HD, Yu H, Pliak MN, Monrad ES, Travin MI et al (2006) Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). Growth Horm IGF Res 16:86
24. Ito Y, Nakachi K, Imai K, Hashimoto S, Watanabe Y, Inaba Y, et al (2005) Stability of frozen serum levels of insulin-like growth factor-I, insulin-like growth factor-II, insulin-like growth factor binding protein-3, transforming growth factor beta, soluble Fas, and superoxide dismutase activity for the JACC study. J Epidemiol 15:67
25. Khosravi J, Diamandi A, Bodani U, Khaja N, Krishna RG (2005) Pitfalls of immunoassay and sample for IGF-I: Comparison of different assay methodologies using various fresh and stored serum samples. Clin Biochem 38:659
26. Elmlinger MW, Zwirner M, Kuhnel W (2005) Stability of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 measured by the IMMULITE automated chemiluminescence assay system in different blood specimens. Clin Lab 51:145
27. Clemmons DR (2001) Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency. Horm Res 2:73
28. Quarmby V, Quan C, Ling V, Compton P, Canova-Davis E (1998) How much insulin-like growth factor I (IGF-I) circulates? Impact of standardization of IGF-I assay accuracy. J Clin Endocrinol Metab 83:1211
29. Chestnut RE, Quarmby V (2002) Evaluation of total IGF-I assay methods using samples from Type I and Type II diabetic patients. J Immunol Meth 1:259
30. Ranke MB, Osterziel KJ, Schweizer R, Schuett B, Weber K, Robbel P, et al (2003) Reference levels of insulin-like growth factor I in the serum of healthy adults: Comparison of four immunoassays. Clin Chem Lab Med 41:1329
31. Attanasio AF, Base DC, Blum W (2000) The hypopituitary control and complications of study (HyposCCS). Topical Endocrinol 8:4
32. Lassarre C, Duron F, Binoux M (2001) Use of the ligand immunofunctional assay for human insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) to analyze IGFBP-3 proteolysis and IGF-I bioavailability in healthy adults, GH-deficient and acromegalic patients, and diabetics. J Clin Endocrinol Metab 86:1942
33. Khosravi J, Diamandi A, Mistry J, Krishna G (1999) The high molecular weight insulin-like growth factor binding protein complex: Epitope mapping, immunoassay, and preliminary clinical evaluation. J Clin Endocrinol Metab 84:2826
34. Frystyk J, Hojlund K, Rasmussen KN, Jorgensne SP, Wildner-Christensen M, Orskov H (2002) Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein-1 in human serum. J Clin Endocrinol Metab 87:260
35. Skjaerbaek C, Frystyk J, Orskov H, Flyvbjerg A (2004) Free IGF-I, IGFBP-1 and the binary complex of IGFBP-1 and IGF-I are increased during human pregnancy. Horm Res 62:215
36. Sadick MD, Intintonli A, Quarmby V, McCoy A, Canova-Davis E, Ling V (1999) Kinase receptor activation (KIRA): A rapid and accurate alternative to end-point bioassays. J Pharm Biomed Anal 19:883